Insulinomatosis: A case report of a multifocal insulin-secreting entity Authors: Connor W. Smith, Elliott K. Fishman, Nicholas J. Roberts, Sudipa Sarkar, Jin He, Ralph H. Hruban Published: 2026 ABSTRACT Insulinomatosis is an exceedingly rare cause of endogenous hyperinsulinemic hypoglycemia, characterized by the presence of multiple insulin-producing neoplasms within the pancreas associated with clinical symptoms of hypoglycemia. We report a case of insulinomatosis in a woman in her sixties with a lifelong history of hypoglycemia and a family history of relatives with symptoms concerning for hypoglycemia. Laboratory evaluation was consistent with hyperinsulinemic hypoglycemia, and further evaluation with various imaging modalities supported the diagnosis of a multifocal neuroendocrine tumor in the pancreas. A complete pancreatectomy was performed, and pathological analysis confirmed a diagnosis of insulinomatosis. This case highlights the need for correlation between biochemical, imaging, histopathologic, and genetic evaluation in diagnosing insulinomatosis. Furthermore, this patient’s case underscores the gaps in understanding the familial and genetic basis of insulinomatosis, which may help inform decision-making in the management of this exceptionally rare disease. Introduction Endogenous hyperinsulinemic hypoglycemia (EHH) is a condition characterized by elevated endogenous insulin secretion causing hypoglycemia. Although there are a variety of etiologies that can cause EHH, it is a very rare condition with a prevalence of 1 case per 4-6 million person-years [1]. EHH typically presents with the “Whipple triad”, characterized by a low blood glucose concentration, symptoms consistent with hypoglycemia, and an alleviation of the symptoms upon consumption of carbohydrates [2]. Most commonly, EHH is caused by a single insulinoma, multiple endocrine neoplasia type 1 (MEN1), postbariatric hypoglycemia syndrome, or noninsulinoma pancreatogenous hypoglycemia syndrome. Although exceedingly rare, insulinomatosis, characterized by multiple insulin-secreting pancreatic neuroendocrine tumors, has been described as an exceptionally rare cause of EHH [3,4]. On computed tomography (CT), features of insulinomatosis include multiple, hypervascular lesions with hyperenhancement on arterial and venous phases. We report the case of a female patient in the 7th decade of life with a pathologically confirmed diagnosis of insulinomatosis. We analyzed the biochemical profile, clinical presentation, and imaging findings of this case to discuss the evaluation and management of this rare entity presenting with EHH. Case report A female patient in the 7th decade of life presented to our institution for management of persistent symptomatic hypoglycemia, which she reported having started when she was 7 years of age. The patient reported intermittent hypoglycemic episodes with sweating, tingling on her tongue, confusion, visual auras, and episodes of intense hunger relieved by food intake. Both exercise and high protein meals precipitated hypoglycemia. The patient noted that both her mother and her son also have a similar long-standing history of intermittent hypoglycemic episodes. Fasting laboratory values revealed an elevated pro-insulin level of 36.3 pmol/L (reference: ≤5 pmol/L), serum insulin of 14.4 µIU/mL (reference: ≤3 µIU/mL), and a C-peptide level of 2.2 ng/mL (reference: ≤0.6 ng/mL) with a blood glucose concentration of 59 mg/dL. Whole exome sequencing (WES) analysis demonstrated no germline pathogenic variants known to be associated with hypoglycemia. In particular, pathogenic germline variants in MAFA were not identified. An abdominal ultrasound (US) demonstrated 2 small, hypoechoic lesions in the pancreas measuring 1.0 × 0.6 cm and 0.9 × 0.6 cm. Subsequent pancreatic protocol CT and 68Ga-DOTATATE positron emission tomography/CT (PET/CT) revealed multiple small, hyperenhancing pancreatic lesions predominantly involving the uncinate process, head, and neck, with smaller suspected lesions throughout the pancreatic body, suggestive of multiple neuroendocrine tumors (Fig. 1). Multiple foci of intense 68Ga-DOTATATE uptake were identified on PET/CT corresponding to the pancreatic lesions found on CT and consistent with multiple neuroendocrine tumors. The pancreatic lesions standardized uptake values (SUV) ranged from 6.1 to 22.2, exceeding the average hepatic uptake (SUV 4.3) and suggesting somatostatin receptor (SSTR) overexpression. Magnetic resonance imaging (MRI) with and without intravenous contrast was performed including MRCP sequences, demonstrating multiple sub-centimeter, cystic lesions with T1 hyperintensity in the pancreatic body and neck. These lesions were correlated with the existing differential diagnosis of a multifocal, neuroendocrine process in the pancreas. An endoscopic ultrasound-guided (EUS) biopsy of the lesion in the pancreatic head was performed and demonstrated a well-differentiated pancreatic neuroendocrine tumor with a Ki-67 index of <2%. Immunolabeling showed neoplastic cells positive for synaptophysin and weakly positive for INSM1. The patient was diagnosed with insulinoma and underwent a total pancreatectomy. Pathological analysis demonstrated 4 well-differentiated pancreatic neuroendocrine tumors, all of which immunolabeled for insulin (Fig. 2). The largest tumor was also positive for synaptophysin and chromogranin. In addition, numerous neuroendocrine microtumors (all <5 mm) were identified, and immunolabeling confirmed that these all uniformly expressed insulin. These findings were consistent with insulinomatosis. The patient was managed with multiple daily insulin injections and later an automated insulin delivery system. A surveillance imaging regimen according to clinical need demonstrated no evidence of recurrence on CT 5 months after surgery.Fig. 1Contrast-enhanced, arterial phase CT scans in the axial view (A-B) with multiplanar reconstruction in the coronal view (C-D) demonstrate multiple small, hyperenhancing lesions in the head, uncinate process, and neck of the pancreas (Arrows—A, B, C, D). MRI was performed and T1-weighted imaging (E-F) revisualized the known pancreatic lesions in the head, body, and neck, demonstrating hyperintensity and cystic features (Arrows—E, F). PET/CT with 68Ga-DOTATATE (G-H) revealed multiple foci of intense DOTATATE uptake throughout the pancreas (Arrows—G, H), and these findings were correlated with the known lesions from previous imaging. The pancreatic lesions SUVs ranged from 6.1-22.2, whereas the average hepatic SUV was 4.3.Fig 1 dummy alt textFig. 2Immunolabeling of 6 areas of the pancreas for insulin. The larger nodules correspond to the 4 well-differentiated pancreatic neuroendocrine tumors found on imaging, located in the head, uncinate process, body, and tail. Note the multiple smaller (<5 mm) micro-tumors which also label exclusively for insulin. No neuroendocrine processes expressing noninsulin hormones were identified.Fig 2 dummy alt text Contrast-enhanced, arterial phase CT scans in the axial view (A-B) with multiplanar reconstruction in the coronal view (C-D) demonstrate multiple small, hyperenhancing lesions in the head, uncinate process, and neck of the pancreas (Arrows—A, B, C, D). MRI was performed and T1-weighted imaging (E-F) revisualized the known pancreatic lesions in the head, body, and neck, demonstrating hyperintensity and cystic features (Arrows—E, F). PET/CT with 68Ga-DOTATATE (G-H) revealed multiple foci of intense DOTATATE uptake throughout the pancreas (Arrows—G, H), and these findings were correlated with the known lesions from previous imaging. The pancreatic lesions SUVs ranged from 6.1-22.2, whereas the average hepatic SUV was 4.3. Immunolabeling of 6 areas of the pancreas for insulin. The larger nodules correspond to the 4 well-differentiated pancreatic neuroendocrine tumors found on imaging, located in the head, uncinate process, body, and tail. Note the multiple smaller (<5 mm) micro-tumors which also label exclusively for insulin. No neuroendocrine processes expressing noninsulin hormones were identified. Discussion Insulinomatosis is an exceptionally rare cause of EHH with approximately 40 cases reported in the literature [5]. The most significant clinical presentation of insulinomatosis is symptomatic hypoglycemic episode. In the case presented here, the patient reported a long-standing history of hypoglycemic symptoms including sweating, paresthesia, confusion, and food-seeking behavior. Biochemical evaluation of patients presenting with hypoglycemic symptoms is a crucial step in the diagnosis of insulinomatosis. According to the NCCN guidelines for neuroendocrine tumors, a fast should be conducted to allow evaluation of serum insulin, pro-insulin, and C-peptide levels in the setting of hypoglycemia [6]. An insulin level above 3 µIU/mL, C-peptide concentrations of over 0.6 ng/mL, and pro-insulin levels at or above 5 pmol/L when fasting blood glucose concentration is below 55 mg/dL are consistent with the presence of an insulinoma. In this case, the fasted laboratory analysis were consistent with insulinoma, revealing a pro-insulin level of 36.3 pmol/L, serum insulin levels of 14.4 µIU/mL, and C-peptide levels of 2.2 ng/mL. Following biochemical evaluation, imaging is a crucial component of the localization, anatomical depiction, and surgical planning for insulinomas within the pancreas. Both CT and magnetic resonance imaging (MRI) are appropriate imaging modalities for the evaluation of an insulinoma [6]. If an insulinoma cannot be localized on conventional imaging, additional diagnostic testing such as (EUS) or selective intra-arterial calcium stimulation may alternatively be used [7]. On CT, an insulinoma typically presents as a hypervascular lesion with hyperenhancement on arterial and venous phases [8]. Insulinomatosis is characterized by the presence of multiple insulin-secreting neuroendocrine tumors in the pancreas. Given the SSTR overexpression characteristic of neuroendocrine tumors, functional imaging with SSTR-specific tracers (eg, 68Ga-DOTATATE) is useful in the assessment of insulinoma and other pancreatic neuroendocrine tumors. SSTR-based imaging options include SSTR-PET/MRI and SSTR-PET/CT, for which 68Ga-DOTATATE and 68Ga-DOTATOC are viable SSTR tracers [9]. Lesions are deemed SSTR positive if their SUV is greater than that of the liver. In this case, the PET/CT demonstrated multiple foci with avid 68Ga-DOTATATE uptake in the pancreas, suggesting the presence of a neuroendocrine tumor with SSTR overexpression. Furthermore, these findings were consistent with the biochemical confirmation of EHH and CT and MR evidence of a multifocal process in the pancreas. However, clinical evidence of EHH with radiological evidence of a multifocal neuroendocrine process cannot reliably distinguish insulinomatosis from MEN1-related insulinomas. Histological analysis is required to achieve a definitive diagnosis between these 2 entities. Histologically, insulinomatosis presents with multiple insulin-expressing neuroendocrine tumors with all tumors immunolabeling exclusively for insulin [10]. Patients with MEN1 can have multiple insulin-expressing, well-differentiated pancreatic neuroendocrine tumors, but they also have other well-differentiated pancreatic neuroendocrine tumors that can express hormones such as glucagon, somatostatin, and pancreatic polypeptide [11]. Histological analysis of this patient’s surgical specimen revealed positive immunostaining by all 4 well-differentiated pancreatic neuroendocrine tumors exclusively for insulin. The numerous microadenomas also exclusively expressed insulin. Combined with the WES panel performed preoperatively, which was negative for a pathogenic germline MEN1 variant or other hypoglycemic driver, the diagnosis of insulinomatosis was made. Pathogenic germline MAFA variants have been reported in several individuals with insulinomatosis [[12], [13], [14], [15]]. Yet, in other individuals with insulinomatosis, there is no identifiable genetic etiology on WES analysis, including the case presented here [12]. It is important to note that this patient’s mother and son also presented with long-standing hypoglycemia of unknown origin, highlighting the need for further research into genetic and familial etiologies of insulinomatosis. Due to its rarity, there are no established guidelines for the management of insulinomatosis. However, a variety of treatment modalities have been reported anecdotally. Surgical interventions such as enucleation or partial pancreatectomy, and pharmacological approaches with insulin antisecretory agents such as diazoxide and everolimus, or somatostatin analogs have been employed. However, up to 95% of patients that are medically managed have persistent symptoms [12]. Often, surgical management with total pancreatectomy is required [5]. Due to the widespread pancreatic involvement in the present case, a total pancreatectomy was performed. Conclusion In conclusion, insulinomatosis is an exceptionally rare but important cause of endogenous hyperinsulinemic hypoglycemia that should be considered when biochemical testing, imaging, and histology suggest the presence of multiple insulin-producing pancreatic lesions. As illustrated by this case, diagnosis requires a multidisciplinary approach. Biochemical confirmation of hyperinsulinemic hypoglycemia, including analysis of pro-insulin, insulin, and C‑peptide levels during fasted hypoglycemia, is a crucial component of the clinical evaluation for insulinomatosis. Both anatomical and functional imaging, particularly CT and 68Ga-DOTATATE PET/CT, can be employed to define the extent of disease and SSTR expression status of pancreatic lesions. Histopathologic confirmation of monohormonal insulin-expressing well-differentiated pancreatic neuroendocrine tumors, and genetic evaluation to exclude causes such as MEN1 are essential to a definitive diagnosis. Surgical resection according to the extent of disease may be required in the event that medical management fails, which is common. Finally, the familial history of hypoglycemia and lack of pathogenic variants in MAFA in this patient highlight the gaps in our understanding of the genetic etiology of insulinomatosis, underscoring the need for broader genomic and etiological investigation for this rare entity. Greater awareness and reporting of such cases will be essential to refine diagnostic criteria, optimize management, and refine our understanding of this condition’s pathogenesis. Patient consent Written informed consent was obtained from the patient for publication of this case report.